Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: mayo clinic + phase 2 + trial  Related to the article below (Last Update: 5/13/2008)

SinuNase? Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis ...
Business Wire (press release), CA - Apr 30, 2008
Researchers at Mayo Clinic were the first to propose that airborne fungus lodged in the mucus lining of the sinuses was the root cause of CS. ...ABPI
DJ HUGIN NEWS/Intercytex part of consortia awarded -2-
VisAvis (Pressemitteilung), Germany - Apr 18, 2008
ICX-SKN is currently in a phase I extension study prior to entering a Phase II trial in the second half of this year. About Intercytex Intercytex is a ...LON:ICX
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment ...
RedOrbit, TX - May 3, 2008
In a phase 2 trial of 57 patients with refractory NSCLC, erlotinib was administered as monotherapy with an objective response rate of 12.3% and a median ...
63-Year-Old Man With Cryptogenic Cirrhosis and Dyspnea
RedOrbit, TX - May 3, 2008
[dagger] Adviser to residents and Consultant in Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. See end of article for correct answers to ...
Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil ...
Journal of American Medical Association (subscription), IL - Apr 22, 2008
Design, Setting, and Participants US Gastrointestinal Intergroup trial RTOG 98-11, a multicenter, phase 3, randomized controlled trial comparing treatment ...
Next-Generation Drug-Eluting Stents A Spirited Step Forward or ...
Journal of American Medical Association (subscription), IL - Apr 22, 2008
These data are encouraging and would qualify as demonstrating biological plausibility and mechanistic effect at the level of a phase 2 study. ...
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Canada NewsWire (press release), Canada - Apr 30, 2008
Pre-Clinical Trial and Collaborative Program In the first quarter of 2008, we reported that a research group led by Dr. Richard Vile of the Mayo Clinic ...ONCY
2008 Annual Meeting of the American Association of Cancer Research
Business Wire (press release), CA - Apr 16, 2008
SNS-032, a potent and selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial in patients with chronic ...SNSS
Drug-Releasing Stent May Improve Outcomes
Newswise (press release) - Apr 22, 2008
?These data are encouraging and would qualify as demonstrating biological plausibility and mechanistic effect at the level of a phase 2 study,? they write. ...

In order to show you the most relevant results, we have omitted some entries very similar to the 9 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma -
PG Richardson, B Barlogie, J Berenson, S Singhal, … - New England Journal of Medicine, 2003 - content.nejm.org
... In this multicenter, open-label, nonrandomized, phase 2 trial, we enrolled ... surface
area twice weekly for 2 weeks, followed ... (DI); Mayo Clinic, Rochester, Minn. ...

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma -
HC Pitot, DB Wender, MJ O'Connell, G Schroeder, RM … - Journal of Clinical Oncology, 1997 - jco.ascopubs.org
... Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. ... JA
Knost, C Ghosh, RJ Kirschling, R Levitt and HE Windschitl Mayo Clinic and Mayo ...

… relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial … -
GA Wiseman, LI Gordon, PS Multani, TE Witzig, S … - Blood, 2002 - ncbi.nlm.nih.gov
... non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. ... Division
of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA. ...

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia -
A Tefferi, RA Mesa, LA Gray, DP Steensma, JK … - Blood, 2002 - bloodjournal.hematologylibrary.org
... Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. ... From
the Mayo Clinic, Rochester, MN; the Mayo Clinic, Scottsdale, AZ; and the Mayo ...

Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low- … -
JC Buckner, D Gesme Jr, JR O'Fallon, JE Hammack, S … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for ...
From the Mayo Clinic and Mayo Foundation, Rochester, MN; Cedar Rapids ...

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B- … -
TE Witzig, CA White, GA Wiseman, LI Gordon, C … - Journal of Clinical Oncology, 1999 - jcojournal.org
... Phase I/II Trial of IDEC ... From the Divisions of Hematology and Nuclear Medicine,
Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN ...

A Phase II trial of green tea in the treatment of patients with androgen independent metastatic … -
A Jatoi, N Ellison, PA Burch, JA Sloan, SR Dakhil, … - Cancer, 2003 - doi.wiley.com
... MATERIALS AND METHODS Overview This multiinstitutional, Phase II trial was conducted
within ... The Institutional Review Board (IRB) of the Mayo Clinic in Rochester ...

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central … -
E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A
North ... From the North Central Cancer Treatment Group; Mayo Clinic College of ...

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma -
TE Witzig, SM Geyer, I Ghobrial, DJ Inwards, R … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell ... From
the Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN ...

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of … -
RA Mesa, DP Steensma, A Pardanani, CY Li, M … - Blood, 2003 - ncbi.nlm.nih.gov
A phase 2 trial of combination low-dose thalidomide and prednisone for the ... Division
of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. ...

Source: Google Scholar

New therapeutic options for newly diagnosed multiple myeloma patients

 

ATLANTA -- Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy. The findings were reported by Craig B. Reeder, M.D., at the American Society of Hematology’s annual meeting.

“For newly diagnosed multiple myeloma patients, this new treatment provides a more frequent, rapid and deeper response when compared to earlier treatment options,” says Dr. Reeder, a Mayo Clinic Cancer Center hematologist/oncologist and lead investigator of the study. “This is the first time we have studied this treatment in newly diagnosed patients with this condition. Compared with past therapies, this new treatment proved to be very successful.”

The team studied 30 patients receiving Cybor-D in the trial. As a relevant contemporaneous control for speed and depth of response, researchers compared 34 patients treated on a recent Mayo Clinic trial of L-Dex. The findings showed that Cybor-D produced a rapid initial decline and percentage reduction in M protein (abnormal protein present in blood of myeloma patients) and a significantly higher rate of good or complete responses than L-Dex. Prophylactic use of acyclovir, a quinolone and antifungal prophylaxis was highly recommended for all patients on the study.

Other Mayo Clinic researchers contributing to the study included Rafael Fonseca, M.D.; Leif Bergsagel, M.D.; S. Vincent Rajkumar, M.D.; Jacy Boesiger; Christine Chen; Martha Lacy, M.D.; Keith Stewart, M.B.Ch.B.; Joseph Hentz and Nicholas Pirooz. Researchers from Princess Margaret Hospital in Toronto, Ontario, also contributed to the study.

Multiple Myeloma

Multiple myeloma, also called myeloma, is an incurable plasma cell (white blood cells in bone marrow) cancer. The disease’s cause is unknown. The American Cancer Society reports that nearly 20,000 people will have been diagnosed with myeloma in 2007 alone. Myeloma interferes with bone marrow function and the immune system, and can cause bone erosion, anemia, infection and possibly kidney failure.

For more information on hematology research at Mayo Clinic Cancer Center, visit http://mayoresearch.mayo.edu/mayo/research/hematologic_malignancies.

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com is available as a resource for your health stories.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.